ALZHEIMER'S DISEASE NEUROIMAGING NETWORK (ADNI)

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这是一项非随机化的自然病史非治疗研究，总共将在美国和加拿大的大约50个地点招募800名受试者，其中包括200名正常对照、400名MCI患者和200名轻度AD患者。 ADNI的主要目标是： 1.制定改进的方法，以实现统一 获取纵向、多点MRI和 轻度阿尔茨海默病患者S病的PET资料 认知障碍(MCI)和老年对照。 2.获取可普遍访问的数据存储库 描述了大脑结构的纵向变化和 新陈代谢。同时，获得临床认知和 用于验证成像替代物的生物标志物数据。 3.开发将提供最大动力的方法 在涉及这些的试验中确定治疗效果 病人。 4.检验基于临床和临床的一系列假说 统计分析中概述的生物标志物数据 一节。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a non-randomized natural history non-treatment study in which a total of 800 subjects including 200 normal controls, 400 individuals with MCI, and 200 subjects with mild AD will be recruited at approximately 50 sites in the United States and Canada. The major goals of the ADNI are to: 1. Develop improved methods which will lead to uniform standards for acquiring longitudinal, multi-site MRI and PET data on patients with Alzheimer s disease (AD), mild cognitive impairment (MCI), and elderly controls. 2. Acquire a generally accessible data repository which describes longitudinal changes in brain structure and metabolism. In parallel, acquire clinical cognitive and biomarker data for validation of imaging surrogates. 3. Develop methods which will provide maximum power to determine treatment effects in trials involving these patients. 4. Test a series of hypotheses based on the clinical and biomarker data as outlined in the statistical analysis section.